Wednesday, 13 November 2019

Japan News

  • Growth ahead for Japan's pharma, medtech

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 08 Jul, 2014

    Singapore: Japan's pharmaceutical market was estimated to be worth $89.1 billion in 2012 and is expected to reach approximately $104.5 billion by 2020 at a compound annual growth rate (CAGR...Read more

  • Evolva, Ajinomoto enter development deal

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 24 Jan, 2013

    Singapore: Evolva Holding SA entered into a collaboration agreement with Ajinomoto, Japan, for the joint development of novel fermentation production routes for a natural functional ingredi...Read more

  • Astellas, Sanwa launch hyperkalemia treatment

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 15 Jan, 2013

    Singapore: Tokyo-headquartered Astellas Pharma and Sanwa Kagaku Kenkyusho, based in Nagoya, Japan, have launched a hyperkalemia treatment Argamate 89.29 percent Granule 5.6g in Japan. Arga...Read more

  • Sanofi seeks approval for Lyxumia in Japan

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 11 Jun, 2012

    Singapore: Sanofi has submitted the marketing authorization application for Lyxumia, (lixisenatide), an investigational once-daily GLP-1 receptor agonist, to the Ministry of Health, Labour ...Read more

  • Hitachi mRNA assay to target personalized medicine

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 19 Nov, 2012

    Singapore: Hitachi Chemical has developed a novel mRNA quantitative assay called Hem(A)+ System that offers a wide range of applications in clinical biomarker discovery and molecular testi...Read more

  • Eisai to launch breast cancer drug in India

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 06 Nov, 2013

    Singapore: With an agenda to expand its footprint in the emerging markets, Japan's Eisai Pharma is launching its novel anti-cancer drug Eribulin, sold under the brand name of Halaven in Ind...Read more

  • Japan approves broader indication for Lyrica

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 01 Mar, 2013

    Singapore: Pfizer Japan has received approval in Japan to replace the current indication of peripheral neuropathic pain for pain treatment Lyrica Capsules (pregabalin) with the new and broa...Read more

  • Rienso gets marketing authorization in Europe

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 26 Jun, 2012

    Singapore: Takeda Pharmaceutical and AMAG Pharmaceuticals have been granted marketing authorization by the European Commission for ferumoxytol, a new intravenous (IV) iron therapy to treat ...Read more

  • Consumers are winners in the BRCA gene case

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 09 Jul, 2013

    In the wake of US Supreme Court's win-win verdict in Association for Molecular Pathology vs Myriad Genetics case, Frost and Sullivan life sciences industry analysts, Mr Justin Collishaw and...Read more

  • Otsuka, Lundbeck sign $825 mn Alzheimer's deal

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 27 Mar, 2013

    Singapore: Denmark-based Lundbeck and Japanese company Otsuka Pharmaceutical have signed a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently i...Read more

  • Takeda drug gets FDA nod for new biologic therapy

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 22 May, 2014

    Singapore: Takeda Pharmaceutical has recieved Food and Drug Administration (FDA) approval for a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults with moderately to s...Read more

  • PGA, Astellas conduct women's day at golf tour

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 28 Feb, 2013

    Singapore: The PGA Tour and subsidiary of Tokyo-based Astellas Pharma launched its first 'Astellas Presents Executive Women's Day', a day-long forum focusing on professional, health-related...Read more

  • Daiichi Sankyo recruits patients for cancer trial

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 21 May, 2012

    Singapore: US-based ArQule and Japanese Daiichi Sankyo have completed the recruitment of patients for their randomized, double-blind, controlled phase III MARQUEE pivotal trial of their inv...Read more

  • World's largest PK/PD group launches service in Asia

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 02 Apr, 2013

    Singapore: Certara, leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, welcomed M...Read more

  • Chugai gives cancer drug license to Debiopharm

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 09 Jan, 2013

    Singapore: Chugai Pharmaceutical and Debiopharm Group entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm), which was discovered by Chugai and is about to e...Read more

  • ASKLEP joins Medidata partner program

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 20 Dec, 2012

    Singapore: ASKLEP, a leading Tokyo-based provider of clinical research services, has joined the Medidata Solutions Partner Program as part of its strategy to expand its existing offerings ...Read more

  • Bayer gets Japan's nod for gastro tumor drug

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 22 Aug, 2013

    Singapore: Bayer has received Japan's approval for Stivarga indicated for the treatment of patients suffering from gastrointestinal stromal tumor (GIST) who have progressed following prior ...Read more

  • Noven Pharma files NDA with US FDA

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 30 Aug, 2012

    Singapore: Noven Pharmaceuticals, a wholly-owned subsidiary of Japanese firm Hisamitsu Pharmaceutical, has submitted a new drug application (NDA) to the US Food & Drug Administration se...Read more